President Donald Trump plans to impose significant import tariffs on pharmaceuticals, a sector previously largely exempt from trade taxes, with potential rates up to 200%. Experts warn that these tariffs could lead to higher drug prices for American consumers, disrupt complex supply chains, and create shortages, particularly for affordable generic drugs. While Trump aims to lower drug costs and encourage domestic manufacturing for national security, analysts suggest that tariffs alone may not achieve these goals without substantial government investment. Companies are already stockpiling and investing in U.S. operations, but fully localized supply chains remain challenging due to reliance on foreign-made ingredients.

Source: Fortune